Last 25 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Royalty Pharma plc's quarterly P/E stands at 13.2x, up 125.9% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 141.4% YoY to 16.2x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 26.65 | 13.16 | 127.05 | 14.28 | 13.65 | 5.83 | 29.17 | 716.27 | 6.35 | 42.41 | 15.23 | 11.78 | — |
| — | +125.9% | +335.5% | -98.0% | +115.0% | -86.3% | +91.5% | +5980.9% | — | +37.1% | +1.2% | -85.6% | — | |
| P/S Ratio | 11.26 | 8.10 | 8.75 | 7.92 | 6.33 | 7.43 | 7.32 | 7.99 | 5.26 | 7.61 | 8.65 | 8.00 | 9.13 |
| — | +9.1% | +19.4% | -0.9% | +20.3% | -2.3% | -15.3% | -0.1% | -42.4% | -28.5% | -27.3% | -24.0% | +3.2% | |
| P/B Ratio | 2.74 | 2.05 | 2.13 | 1.84 | 1.45 | 1.64 | 1.61 | 1.84 | 1.24 | 1.70 | 1.90 | 2.23 | 2.17 |
| — | +25.5% | +32.0% | -0.1% | +16.8% | -3.9% | -14.9% | -17.4% | -42.6% | -27.3% | -22.6% | -4.5% | +9.1% | |
| P/FCF | 10.75 | 7.70 | 11.86 | 7.55 | 5.06 | 5.96 | 5.98 | 6.83 | 4.06 | 7.11 | 7.66 | 5.29 | 9.06 |
| — | +29.2% | +98.3% | +10.6% | +24.6% | -16.2% | -22.0% | +29.0% | -55.2% | -37.2% | -31.0% | -58.8% | -12.8% | |
| EV / EBITDA | 22.51 | 16.20 | 43.34 | 12.29 | 13.56 | 6.71 | 22.16 | 146.66 | 5.95 | 35.18 | 23.55 | 14.06 | 48.92 |
| — | +141.4% | +95.6% | -91.6% | +128.0% | -80.9% | -5.9% | +942.8% | -87.8% | -11.4% | +16.6% | -56.2% | +20.2% | |
| EV / EBIT | 22.51 | 13.25 | 43.34 | 12.29 | 13.56 | 6.71 | 22.16 | 146.66 | 5.95 | 35.51 | 23.69 | 14.11 | 48.92 |
| — | +97.5% | +95.6% | -91.6% | +128.0% | -81.1% | -6.4% | +939.7% | -87.8% | -10.5% | +17.3% | -57.2% | +15.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Royalty Pharma plc's operating margin was 70.1% in Q3 2025, up 33.9 pp QoQ and down 60.1 pp YoY. The trailing four-quarter average of 65.3% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 48.3% | 55.2% | 82.6% | 45.4% |
| — | 0.0% | 0.0% | 0.0% | 0.0% | +106.9% | +81.2% | +21.0% | +120.2% | +3.3% | -31.3% | +23.0% | -15.5% | |
| Operating Margin | 65.6% | 70.1% | 36.3% | 94.0% | 60.9% | 130.2% | 50.2% | -13.0% | 102.8% | 28.2% | 46.2% | 70.0% | -85.3% |
| — | -46.1% | -27.8% | +823.7% | -40.8% | +361.0% | +8.5% | -118.5% | +220.5% | -15.8% | -34.4% | +79.1% | -420.1% | |
| Net Margin | 32.4% | 47.3% | 5.2% | 41.9% | 35.1% | 96.3% | 19.0% | 0.8% | 82.9% | 13.4% | 42.3% | 49.8% | -80.6% |
| — | -50.9% | -72.5% | +4886.3% | -57.7% | +616.4% | -55.1% | -98.3% | +202.9% | -45.9% | -25.6% | +441.0% | -5972.0% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.7% | 3.0% | 0.3% | 2.4% | 2.0% | 5.4% | 1.0% | 0.0% | 5.0% | 0.7% | 2.3% | 3.5% | -4.6% |
| — | -44.6% | -69.9% | +4843.6% | -59.8% | +631.3% | -55.1% | -98.6% | +209.9% | -45.7% | -21.8% | +593.8% | -6071.5% | |
| ROA | 4.1% | 1.5% | 0.2% | 1.3% | 1.1% | 3.0% | 0.6% | 0.0% | 3.1% | 0.4% | 1.3% | 2.0% | -2.6% |
| — | -49.8% | -72.2% | +4425.2% | -62.6% | +596.8% | -54.6% | -98.5% | +216.0% | -45.7% | -23.2% | +577.8% | -6004.0% | |
| ROIC | 6.7% | 1.9% | 0.9% | 2.4% | 1.6% | 3.4% | 1.3% | -0.4% | 3.0% | 0.8% | 1.3% | 2.4% | -2.3% |
| — | -45.3% | -27.9% | +771.0% | -47.0% | +341.2% | +4.8% | -114.9% | +230.9% | -14.8% | -31.6% | +127.9% | -414.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Royalty Pharma plc's Debt/EBITDA ratio is 20.9x, down from 50.2x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 126.8% YoY to 3.48x, strengthening the short-term liquidity position. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.91 | 0.93 | 0.84 | 0.78 | 0.74 | 0.74 | 0.78 | 0.62 | 0.61 | 0.64 | 0.73 | 0.73 | 0.75 |
| — | +25.7% | +8.0% | +25.0% | +21.0% | +15.9% | +7.4% | -14.2% | -18.6% | -6.3% | +6.4% | +3.6% | +7.9% | |
| Debt / EBITDA | 5.74 | 20.93 | 50.23 | 15.27 | 19.03 | 8.72 | 31.23 | 153.64 | 8.02 | 40.11 | 28.48 | 14.82 | 53.44 |
| — | +140.1% | +60.8% | -90.1% | +137.2% | -78.3% | +9.7% | +936.4% | -85.0% | +8.4% | +51.4% | -52.9% | +19.9% | |
| Current Ratio | 0.97 | 3.48 | 1.26 | 1.56 | 1.44 | 1.54 | 9.35 | 12.52 | 7.90 | 13.51 | 2.52 | 2.36 | 2.19 |
| — | +126.8% | -86.5% | -87.6% | -81.8% | -88.6% | +271.3% | +431.5% | +260.6% | +552.8% | -86.9% | -89.3% | -87.0% | |
| Quick Ratio | 0.97 | 3.48 | 1.26 | 1.56 | 1.44 | 1.54 | 9.35 | 12.52 | 7.90 | 13.51 | 2.52 | 2.36 | 2.19 |
| — | +126.8% | -86.5% | -87.6% | -81.8% | -88.6% | +271.3% | +431.5% | +260.6% | +552.8% | -86.9% | -89.3% | -87.0% | |
| Interest Coverage | 5.07 | 5.37 | 3.06 | 8.19 | 5.50 | 11.05 | 5.50 | -1.67 | 12.97 | 3.29 | 5.30 | 10.20 | -10.28 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonRoyalty Pharma plc's current P/E is 26.6x. The average P/E over the last 4 quarters is 42.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Royalty Pharma plc's current operating margin is 65.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Royalty Pharma plc's business trajectory between earnings reports.